Expands BD's portfolio of smart connected care solutions with leading monitoring technologies, including advanced AI-enabled clinical decision toolsCombination of leading monitoring and infusion platforms enables future innovation opportunities for closed–loop monitoring and treatment, integrating combined company data sets and interoperability capabilitiesBusiness renamed as BD Advanced Patient Monitoring, will be based in Irvine, Calif.

通过领先的监测技术（包括先进的人工智能临床决策工具）扩展了BD的智能连接护理解决方案组合。领先的监测和输液平台的结合为闭环监测和治疗提供了未来的创新机会，整合了公司数据集和互操作能力。更名为BD advanced Patient monitoring的业务将位于加利福尼亚州欧文。

and become part of BD Medical segmentKatie Szyman will continue to lead BD Advanced Patient Monitoring as worldwide presidentFRANKLIN LAKES, N.J., Sept. 3, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of Edwards Lifesciences' Critical Care product group, which will be renamed as BD Advanced Patient Monitoring..

并成为BD医疗部门的一部分Katie Szyman将继续领导BD Advanced Patient Monitoring，担任全球总裁新泽西州兰克林湖，2024年9月3日/PRNewswire/--BD（Becton，Dickinson and Company）（纽约证券交易所：BDX），一家领先的全球医疗技术公司，今天宣布已完成对爱德华兹生命科学重症监护产品集团的收购，该集团将更名为BD Advanced Patient Monitoring。

BD Advanced Patient Monitoring is a global leader in advanced monitoring solutions that expands BD's portfolio of smart connected care solutions with its growing set of leading monitoring technologies, advanced AI-enabled clinical decision tools and robust innovation pipeline. BD Advanced Patient Monitoring's technologies are often used simultaneously with the BD Alaris™ Infusion System in the operating room or intensive care units.

BD Advanced Patient Monitoring是先进监测解决方案的全球领导者，该解决方案通过不断增长的领先监测技术、先进的人工智能临床决策工具和强大的创新渠道，扩展了BD的智能连接护理解决方案组合。BD Advanced Patient Monitoring的技术通常与手术室或重症监护室中的BD Alaris™输液系统同时使用。

The combination of BD's new advanced monitoring and existing infusion platforms enables future innovation opportunities for closed-loop hemodynamic monitoring and IV fluid and medication administration by integrating combined company data sets and interoperability capabilities..

BD新的先进监测和现有输液平台的结合，通过整合公司数据集和互操作能力，为闭环血流动力学监测以及静脉输液和药物管理提供了未来的创新机会。

'The health care industry is being redefined by AI, robotics, and autonomous solutions, and our team continues to accelerate the application of these new technologies to improve the quality and cost of patient care around the world,' said Tom Polen, chairman, chief executive officer and president of BD.

BD董事长、首席执行官兼总裁汤姆·波伦（TomPolen）表示：“人工智能、机器人技术和自主解决方案正在重新定义医疗保健行业，我们的团队将继续加速这些新技术的应用，以提高全球患者护理的质量和成本。”

'Today, BD is proud to welcome BD Advanced Patient Monitoring, whose leading technologies, AI-enabled solutions and strong innovation pipeline expand our portfolio of smart, connected care solutions, create significant value for customers, and put BD at the forefront of enabling the future of health care.'.

“今天，BD很自豪地欢迎BD Advanced Patient Monitoring，其领先的技术、支持人工智能的解决方案和强大的创新渠道扩大了我们的智能互联护理解决方案组合，为客户创造了巨大的价值，并将BD置于实现未来医疗保健的最前沿。”

BD Advanced Patient Monitoring's portfolio includes the gold-standard Swan Ganz pulmonary artery catheter, minimally invasive sensors, noninvasive cuffs, tissue oximetry sensors and monitors. Its smart technologies are driven by advanced data analytics with machine learning and AI-based predictive and prescriptive algorithms to help clinicians better understand current and future patient conditions and provide clinical decision support tools..

BD Advanced Patient Monitoring的产品组合包括金标准Swan-Ganz肺动脉导管、微创传感器、无创袖带、组织血氧仪传感器和监护仪。其智能技术由先进的数据分析和机器学习以及基于AI的预测和规定算法驱动，以帮助临床医生更好地了解当前和未来的患者状况，并提供临床决策支持工具。

BD Advanced Patient Monitoring will operate as a separate business unit within BD's Medical segment to align with its smart connected care approach, and it will maintain its presence in Irvine, Calif. Katie Szyman, who has served as corporate vice president of the business under Edwards since 2015, has been named worldwide president of BD Advanced Patient Monitoring, reporting to Mike Garrison, executive vice president and president of the BD Medical segment..

BD Advanced Patient Monitoring将作为BD医疗部门的一个独立业务部门运营，以与其智能互联护理方法保持一致，并将保持其在加利福尼亚州欧文市的业务。Katie Szyman自2015年以来一直担任爱德华兹公司业务副总裁，已被任命为BD Advanced Patient Monitoring全球总裁，向BD医疗部门执行副总裁兼总裁Mike Garrison汇报。

The completion of the acquisition is expected to have an immaterial impact to the previously disclosed BD fiscal year 2024 guidance provided in the August 1 third quarter earnings news release. For additional information about the transaction, please reference the Investor Presentation and Transaction Announcement Press Release issued on June 3, 2024, both available on the Investor page on BD.com..

收购的完成预计将对8月1日第三季度收益新闻稿中提供的先前披露的BD 2024财年指南产生不重大影响。有关交易的更多信息，请参阅2024年6月3日发布的投资者介绍和交易公告新闻稿，可在BD.com的投资者页面上找到。

About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers.

关于BDBD是世界上最大的全球医疗技术公司之一，正在通过改进医疗发现、诊断和护理服务来促进世界健康。该公司通过开发创新技术、服务和解决方案来支持医疗保健前线的英雄，这些技术、服务和解决方案有助于推进患者的临床治疗和医疗保健提供者的临床过程。

BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics.

BD及其70000多名员工充满热情并致力于帮助提高临床医生护理过程的安全性和效率，使实验室科学家能够准确检测疾病，并提高研究人员开发下一代诊断和治疗方法的能力。

BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

BD在几乎每个国家都有业务，并与世界各地的组织合作，以解决一些最具挑战性的全球健康问题。通过与客户密切合作，BD可以帮助提高成果，降低成本，提高效率，提高安全性并扩大医疗保健的范围。

For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and on X (formerly known as Twitter) @BDandCo..

有关BD的更多信息，请访问BD.com或通过LinkedIn www.LinkedIn.com/company/bd1/和X（以前称为Twitter）@BDandCo与我们联系。

Forward-Looking StatementsThis press release contains forward-looking statements (as defined under Federal securities laws) regarding the anticipated benefits of the acquisition of Edwards Lifesciences' Critical Care product group. These statements are based on the current expectations of BD management and are subject to a number of risks and uncertainties regarding the business and the acquisition, and actual results may differ materially from any anticipated results described, implied or projected in any forward-looking statement.

前瞻性声明本新闻稿包含有关收购爱德华兹生命科学重症监护产品集团的预期收益的前瞻性声明（根据联邦证券法的定义）。这些报表基于BD管理层当前的预期，并受到业务和收购方面的许多风险和不确定性的影响，实际结果可能与任何前瞻性报表中描述、暗示或预测的任何预期结果存在重大差异。

These risks and uncertainties include, but are not limited to, risks relating to the integration of the Critical Care Product group's operations, products and employees into BD and the time and resources required to do so and the possibility that the anticipated benefits of the acquisition will not be realized or will not be realized within the expected timeframe; the loss of key senior management or other associates; competitive factors, including the development of new technologies by other companies and pricing and market share pressures; changes in healthcare or other governmental regulation; risks relating to the ability to maintain favorable supplier arrangements and relationships; changes in regional, national or foreign economic conditions, as well as other factors discussed in BD's filings with the Securities Exchange Commission.

这些风险和不确定性包括但不限于与将重症监护产品组的运营、产品和员工整合到BD中有关的风险，以及这样做所需的时间和资源，以及收购的预期收益无法实现或无法在预期时间内实现的可能性；关键高级管理人员或其他关联人员的流失；竞争因素，包括其他公司开发新技术以及定价和市场份额压力；医疗保健或其他政府法规的变化；与维持良好供应商安排和关系的能力有关的风险；地区、国内或国外经济状况的变化，以及BD向证券交易委员会提交的文件中讨论的其他因素。

BD does not intend to update any forward-looking statements to reflect events or circumstances after the date hereof, except as required by applicable laws or regulations..

BD不打算更新任何前瞻性声明以反映本协议日期后的事件或情况，除非适用法律或法规要求。